GnRH agonist releasing implants could, in theory, have the potential to impact the probability of certain undesirable conditions (such as obesity and cancer) while still offering contraceptive benefits. This evidence concerns the gene GNRH1 and obesity due to melanocortin 4 receptor deficiency.